Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.76 |
| ▸ | RAB9A | P51151 | 12/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.76 |
| ▸ | MAPT | P10636 | 8/20 | 0.76 |
| ▸ | MEN1 | O00255 | 7/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.76 |
| ▸ | HPGD | P15428 | 6/20 | 0.76 |
| ▸ | GLA | P06280 | 2/20 | 0.76 |
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | ATM | Q13315 | 2/20 | 0.61 |
| ▸ | GFER | P55789 | 2/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.55 |
| ▸ | RELA | Q04206 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24106599 | 0.98 | NPC1 (0.73) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL30965463 | 0.98 | NPC1 (0.73) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL17199120 | 0.90 | NPC1 (0.81) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL10590678 | 0.90 | SMN1; SMN2 (0.61) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL29622897 | 0.87 | NPC1 (0.76) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL1734841 | 0.87 | NPC1 (0.76) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL5655662 | 0.86 | NPC1 (0.86) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL2245075 | 0.86 | RAB9A (1.00) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL23748392 | 0.86 | NPC1 (0.73) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL28292707 | 0.85 | RAB9A (0.96) | NPC1RAB9AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| US-12473266-B2 | Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4247800-B1 | N-SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2024-11-13 | — | — | EP | disclosed |
| US-20240156872-A1 | Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2024-05-16 | — | — | US | disclosed |
| CN-113195084-B | Benzoxazoles and related compounds useful as modulators of chaperone mediated autophagy | 阿尔伯爱因斯坦医学院 | 2024-04-09 | — | — | CN | disclosed |
| US-20230286930-A1 | N -SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286930-A1 | N -SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286930-A1 | N -SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-116438166-A | N-substituted 4- (1, 3-aryloxazol-2-yl) phenyl compounds for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2023018801-A1 | COMPOSITIONS AND METHODS OF ENRICHING HEMATOPOIETIC STEM CELL POPULATIONS AND METHODS OF USE THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-2170396-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-04-07 | — | — | EP | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| WO-2009019504-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-12 | — | — | WO | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286930-A1 | N -SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP2E1, CYP7A1 | NPC1 71/4885RAB9A 2085/4885KDM4E 918/4885 |
| US-12473266-B2 | Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators | CLPX, SQSTM1, ATG7 | NPC1 807/4885RAB9A 77/4885KDM4E 3005/4885 |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | NPC1 2477/4885RAB9A 3748/4885KDM4E 3311/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | NPC1 2477/4885RAB9A 3748/4885KDM4E 3311/4885 |
| US-20240156872-A1 | Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations | SQSTM1, MCL1, HSPA2 | NPC1 1454/4885RAB9A 701/4885KDM4E 3240/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | NPC1 3637/4885RAB9A 4325/4885KDM4E 2080/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | NPC1 3637/4885RAB9A 4325/4885KDM4E 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.